Japan· JP-3999027F1039
バゼドキシフェン酢酸塩
A bazedoxifene product containing バゼドキシフェン酢酸塩, registered in Japan by 沢井製薬, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Bazedoxifene is registered in 10 of 19 countries.
Countries holding a registration under ATC G03XC02 (bazedoxifene), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 6 of them publish a price we can compare per daily dose
Bazedoxifene · ATC G03XC02
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Polandprice
Price per daily dose
What a daily dose of bazedoxifene costs, country by country.
Normalised to the WHO defined daily dose (20 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Bazedoxifene · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- IT Italy$1.34
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- バゼドキシフェン酢酸塩
- Manufacturer
- 沢井製薬
- Country
- Japan (JP)
- ATC code
- G03XC02
- ATC class
- Bazedoxifene
- Defined daily dose
- 20 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
6 interactions on record for bazedoxifene.
Graded by severity as the source publishes them — 6 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bazedoxifene · interactions on record
6 records
- 6 moderate
Most severe, free to view
- MegestrolG03AC05moderate
- MedroxyprogesteroneG03AC06moderate
- MedroxyprogesteroneG03DA02moderate
- MegestrolG03DB02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under G03XC02
Bazedoxifene, as other registers publish it.
- PolandConbrizaPfizer Europe MA EEIG
- DenmarkConbrizaPfizer Europe MA EEIG
- IcelandConbrizaPfizer Europe MA EEIG*
- FinlandConbrizaPfizer Europe MA EEIG
- CzechiaCONBRIZAPfizer Europe MA EEIG, Bruxelles
- CzechiaCONBRIZAPfizer Europe MA EEIG, Bruxelles
- CzechiaCONBRIZAPfizer Europe MA EEIG, Bruxelles
- CzechiaCONBRIZAPfizer Europe MA EEIG, Bruxelles
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d2777d87-f195-4ac1-8b98-972323d4e9a9 GET /v1/drugs/d2777d87-f195-4ac1-8b98-972323d4e9a9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２０ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3999027F1039",
"category": "内用薬",
"price_yen": 25.7,
"generic_name": "バゼドキシフェン酢酸塩",
"product_name_jp": null,
"therapeutic_class": "3999",
"transitional_expiry": null
}See everything about bazedoxifene.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.